开云app官网登录入口网页版-官方正版

#联合免疫治疗#

16篇内容 | 648人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1807666, encodeId=1804180e6663d, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=西湖大学马丽佳团队开发In-library Ligation策略，促进联合免疫治疗靶点高通量筛选, objectType=article, longId=729613, objectId=aa84e2961341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa84e2961341, replyNumber=0, likeNumber=83, createdTime=2022-11-16, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa84e2961341, moduleTitle=西湖大学马丽佳团队开发In-library Ligation策略，促进联合免疫治疗靶点高通量筛选, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa84e2961341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807663, encodeId=331d180e66309, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, objectType=article, longId=264987, objectId=306f26498e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306f26498e26, replyNumber=0, likeNumber=93, createdTime=2022-02-06, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306f26498e26, moduleTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=306f26498e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807664, encodeId=9f7e180e66442, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, objectType=article, longId=293503, objectId=164d293503c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d293503c3, replyNumber=0, likeNumber=79, createdTime=2022-08-06, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d293503c3, moduleTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=164d293503c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807665, encodeId=e6a4180e6659f, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=哪种TK I不可联合免疫治疗？, objectType=article, longId=294710, objectId=d9d5294e10d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9d5294e10d6, replyNumber=0, likeNumber=57, createdTime=2022-02-11, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9d5294e10d6, moduleTitle=哪种TK I不可联合免疫治疗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9d5294e10d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807662, encodeId=6d3a180e662fa, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=54, createdTime=2022-08-02, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807661, encodeId=cb79180e66141, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Front Oncol：安罗替尼（anlotinib）联合或不联合免疫治疗在晚期非小细胞肺癌的真实世界的疗效, objectType=article, longId=220046, objectId=513b2200469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=513b2200469c, replyNumber=0, likeNumber=72, createdTime=2022-01-07, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=513b2200469c, moduleTitle=Front Oncol：安罗替尼（anlotinib）联合或不联合免疫治疗在晚期非小细胞肺癌的真实世界的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=513b2200469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807660, encodeId=7848180e66002, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的, objectType=article, longId=218270, objectId=6a462182e009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a462182e009, replyNumber=0, likeNumber=62, createdTime=2022-03-31, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a462182e009, moduleTitle=Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a462182e009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807659, encodeId=b760180e6595d, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=2021CSCO：肺癌精准放疗联合免疫治疗的现在与展望, objectType=article, longId=217856, objectId=6f7621e856ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f7621e856ce, replyNumber=0, likeNumber=75, createdTime=2021-11-15, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f7621e856ce, moduleTitle=2021CSCO：肺癌精准放疗联合免疫治疗的现在与展望, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6f7621e856ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807657, encodeId=4d09180e65712, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=张华教授谈抗血管联合免疫治疗治疗现状及前景, objectType=article, longId=175574, objectId=3ff41e557403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff41e557403, replyNumber=0, likeNumber=87, createdTime=2019-11-24, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff41e557403, moduleTitle=张华教授谈抗血管联合免疫治疗治疗现状及前景, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3ff41e557403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807658, encodeId=d96f180e6583e, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, objectType=article, longId=193346, objectId=688d193346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688d193346bb, replyNumber=0, likeNumber=82, createdTime=2020-08-30, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688d193346bb, moduleTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=688d193346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807654, encodeId=e9b3180e654fb, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Nature：一个大胆的想法，改善肿瘤联合免疫治疗疗效, objectType=article, longId=167104, objectId=e4e816e1043e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e816e1043e, replyNumber=0, likeNumber=94, createdTime=2020-01-23, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e816e1043e, moduleTitle=Nature：一个大胆的想法，改善肿瘤联合免疫治疗疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e4e816e1043e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807655, encodeId=8a08180e6554d, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=联合免疫治疗在晚期软组织肉瘤治疗中崭露头角, objectType=article, longId=168161, objectId=9867168161eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9867168161eb, replyNumber=0, likeNumber=85, createdTime=2020-01-05, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9867168161eb, moduleTitle=联合免疫治疗在晚期软组织肉瘤治疗中崭露头角, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9867168161eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807656, encodeId=e964180e656fc, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, objectType=article, longId=168996, objectId=019516899631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019516899631, replyNumber=0, likeNumber=89, createdTime=2019-07-24, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019516899631, moduleTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=019516899631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807653, encodeId=9e06180e653ef, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, objectType=article, longId=127483, objectId=749e12e48327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749e12e48327, replyNumber=0, likeNumber=80, createdTime=2018-08-20, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749e12e48327, moduleTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=749e12e48327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807652, encodeId=f22e180e65270, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=CLIN CANCER RES：PD-1阻断时机对联合免疫治疗疗效至关重要, objectType=article, longId=118085, objectId=19f611808541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f611808541, replyNumber=0, likeNumber=72, createdTime=2018-08-23, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f611808541, moduleTitle=CLIN CANCER RES：PD-1阻断时机对联合免疫治疗疗效至关重要, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19f611808541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807651, encodeId=166a180e65106, content=<a href='/topic/show?id=3e5b806e922' target=_blank style='color:#2F92EE;'>#联合免疫治疗#</a>, objectTitle=CUA 2015：前列腺癌的联合免疫治疗, objectType=article, longId=55846, objectId=26d8558460d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d8558460d, replyNumber=0, likeNumber=74, createdTime=2016-04-09, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d8558460d, moduleTitle=CUA 2015：前列腺癌的联合免疫治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26d8558460d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

联合免疫治疗

2020-05-29

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

西湖大学马丽佳团队开发In-library Ligation策略，促进联合免疫治疗靶点高通量筛选

2022-11-16

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效

2022-02-06

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗

2022-08-06

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

哪种TK I不可联合免疫治疗？

2022-02-11

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2022-08-02

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

Front Oncol：安罗替尼（anlotinib）联合或不联合免疫治疗在晚期非小细胞肺癌的真实世界的疗效

2022-01-07

cathymary (审核中...)

前往app查看评论内容

#联合免疫治疗#

Front Oncol：可切除NSCLC患者术前化疗联合免疫治疗是安全可行的

2022-03-31

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

2021CSCO：肺癌精准放疗联合免疫治疗的现在与展望

2021-11-15

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

张华教授谈抗血管联合免疫治疗治疗现状及前景

2019-11-24

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）

2020-08-30

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

Nature：一个大胆的想法，改善肿瘤联合免疫治疗疗效

2020-01-23

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

联合免疫治疗在晚期软组织肉瘤治疗中崭露头角

2020-01-05

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破

2019-07-24

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代

2018-08-20

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

CLIN CANCER RES：PD-1阻断时机对联合免疫治疗疗效至关重要

2018-08-23

柳叶一刀 (审核中...)

前往app查看评论内容

#联合免疫治疗#

CUA 2015：前列腺癌的联合免疫治疗

2016-04-09

科室
- - 订阅+
  - 更多科室
工具
服务